Overview

Anakinra and Kawasaki Disease

Status:
Completed

Trial end date:
2019-02-18

Target enrollment:

Participant gender:

Summary

The study is designed to assess the efficacy and safety of anakinra, an interleukin 1 receptor antagonist, in patients with Kawasaki disease who failed to respond to standard treatment:e.g. one infusion of 2g/kg of intravenous immunoglobulins.

Phase:

Phase 2

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborators:

Sobi
Swedish Orphan Biovitrum

Treatments:

Interleukin 1 Receptor Antagonist Protein